MX369626B - Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia. - Google Patents

Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.

Info

Publication number
MX369626B
MX369626B MX2014014412A MX2014014412A MX369626B MX 369626 B MX369626 B MX 369626B MX 2014014412 A MX2014014412 A MX 2014014412A MX 2014014412 A MX2014014412 A MX 2014014412A MX 369626 B MX369626 B MX 369626B
Authority
MX
Mexico
Prior art keywords
prevention
treatment
compositions
rabies
methods related
Prior art date
Application number
MX2014014412A
Other languages
English (en)
Other versions
MX2014014412A (es
Inventor
Shen Enyun
Ren Shiqi
Original Assignee
Mountgate Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountgate Group Ltd filed Critical Mountgate Group Ltd
Publication of MX2014014412A publication Critical patent/MX2014014412A/es
Publication of MX369626B publication Critical patent/MX369626B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos contra la rabia que pueden unir y neutralizar el virus de la rabia. Los anticuerpos de la tecnología son útiles solos o en combinación con terapias conocidas en la técnica para el tratamiento o prevención de la infección de rabia.
MX2014014412A 2012-05-24 2012-05-24 Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia. MX369626B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/076012 WO2013174003A1 (en) 2012-05-24 2012-05-24 Compositions and methods related to prevention and treatment of rabies infection

Publications (2)

Publication Number Publication Date
MX2014014412A MX2014014412A (es) 2015-07-21
MX369626B true MX369626B (es) 2019-11-13

Family

ID=49623026

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014412A MX369626B (es) 2012-05-24 2012-05-24 Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.

Country Status (12)

Country Link
US (1) US9290564B2 (es)
EP (2) EP3508497A1 (es)
JP (1) JP5868549B2 (es)
KR (1) KR101937733B1 (es)
CN (1) CN104603149B (es)
BR (1) BR112014029274B1 (es)
HK (1) HK1210187A1 (es)
IN (1) IN2014KN02831A (es)
MX (1) MX369626B (es)
PH (1) PH12014502628B1 (es)
SG (1) SG11201408330XA (es)
WO (1) WO2013174003A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5868549B2 (ja) * 2012-05-24 2016-02-24 マウントゲイト グループ リミテッド 狂犬病感染の予防および治療に関する組成物および方法
CN104193823B (zh) * 2014-08-22 2019-06-11 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒特异性人源抗体及应用
SG11201701565PA (en) 2014-09-03 2017-03-30 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
DK3220947T3 (da) * 2014-11-18 2020-11-30 Humabs Biomed S A Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf
WO2017027805A1 (en) * 2015-08-13 2017-02-16 University Of Massachusetts Human antibodies against rabies and uses thereof
EP3848393A1 (en) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
KR101990795B1 (ko) * 2017-12-07 2019-06-19 대한민국 광견병바이러스 특이 항체 및 이를 이용한 광견병바이러스 검출방법
CN109970852B (zh) * 2019-04-01 2020-10-13 浙江大学 分泌抗狂犬病毒m蛋白单克隆抗体的杂交瘤细胞株及应用
CN111171145B (zh) * 2020-01-21 2021-11-05 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒单克隆抗体、制备方法及用途
CN111888470A (zh) * 2020-08-12 2020-11-06 赵静 具有中和狂犬病病毒效能的冲洗液及其活性检测方法
WO2023215746A2 (en) * 2022-05-02 2023-11-09 Javelin Oncology, Inc. Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use
CN116327925B (zh) * 2022-09-27 2024-08-23 兴盟生物医药(苏州)有限公司 一种抗狂犬病毒人源抗体的组合制剂及应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5028530A (en) 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
DE3590766T (es) 1985-03-30 1987-04-23
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
US5304389A (en) 1991-06-18 1994-04-19 Mitsubishi Kasei Corporation Non-hygroscopic icing composition
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
EP1149913A1 (en) 1990-11-09 2001-10-31 GILLIES, Stephen D. Cytokine immunoconjugates
US6106835A (en) 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
WO1992019973A1 (en) 1991-04-26 1992-11-12 Surface Active Limited Novel antibodies, and methods for their use
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU665221B2 (en) 1991-12-02 1995-12-21 Cambridge Antibody Technology Limited Production of anti-self antibodies from antibody segment repertoires and displayed on phage
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
WO2001005950A2 (en) 1999-07-20 2001-01-25 Morphosys Ag Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US7094571B2 (en) 2000-10-27 2006-08-22 The Board Of Regents Of The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7083945B1 (en) 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
WO2011080765A2 (en) * 2010-01-04 2011-07-07 Indian Immunologicals Limited Recombinant human bivalent diabody against rabies virus and uses thereof
CN101812132B (zh) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗狂犬病毒糖蛋白中和性抗体(RVFab3)
CN101812131B (zh) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗狂犬病毒糖蛋白中和性抗体(RVFab8)
CN101812130B (zh) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5)
JP5868549B2 (ja) * 2012-05-24 2016-02-24 マウントゲイト グループ リミテッド 狂犬病感染の予防および治療に関する組成物および方法

Also Published As

Publication number Publication date
BR112014029274B1 (pt) 2022-02-15
HK1210187A1 (en) 2016-04-15
MX2014014412A (es) 2015-07-21
EP2855521A4 (en) 2016-03-02
US9290564B2 (en) 2016-03-22
KR101937733B1 (ko) 2019-01-11
IN2014KN02831A (es) 2015-05-08
KR20150016590A (ko) 2015-02-12
CN104603149B (zh) 2017-06-30
JP5868549B2 (ja) 2016-02-24
EP3508497A1 (en) 2019-07-10
WO2013174003A1 (en) 2013-11-28
SG11201408330XA (en) 2015-01-29
PH12014502628A1 (en) 2015-01-26
PH12014502628B1 (en) 2015-01-26
JP2015525206A (ja) 2015-09-03
US20150110781A1 (en) 2015-04-23
EP2855521A1 (en) 2015-04-08
CN104603149A (zh) 2015-05-06
BR112014029274A2 (pt) 2018-04-24

Similar Documents

Publication Publication Date Title
PH12014502628B1 (en) Compositions and methods related to the prevention and treatment of rabies infection
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
MX2015003416A (es) Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer.
NZ711946A (en) Newcastle disease viruses and uses thereof
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2016002571A (es) Regulador de ph de transduccion.
IN2014KN00848A (es)
IN2014DN08721A (es)
PH12017500864A1 (en) Anti-notch1 antibodies
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MY186066A (en) Anti-phf-tau antibodies and their uses
IN2014DN08481A (es)
TW201611843A (en) Methods of treatment with arginine deiminase
IN2015DN00636A (es)
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
EP2869821A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND INHIBITING VIRAL INFECTIONS
EP2802353A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
IN2014DN08385A (es)
EP2663327A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases
MY171384A (en) Composition and methods related to the prevention and treatment of rabies infection
PT2838903T (pt) Métodos e composições para tratamento de infeções virais

Legal Events

Date Code Title Description
FG Grant or registration